When Apellis Pharmaceuticals (APLS) secured FDA approval for EMPAVELI in C3 glomerulopathy and IC-MPGN last summer, the stock was trading near $28. Today it sits at $19.96, down 31% over the past year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback